Overall, 26.4% of 6,584 cases tested PRRSV-positive in December, a moderate decrease from 28.7% of 6,980 in November;
• Positivity in the adult/sow category in December was 23.47% (726 of 3,093), a moderate increase from 21.38% (665 of 3,110) in November;
• Positivity in the wean-to-market category in December was 41.89% (798 of 1,905), a moderate decrease from 46.17% (1,055 of 2,285) in November;
• Overall PRRSV-percentage of positive cases was 3 standard deviations above state-specific baselines in IA, IN, OK, and SD; Overall, 7.83% of 3,947 cases tested PEDV-positive in December, similar to 6.51% of 3,734 in November;
• Positivity in the adult/sow category in December was 6.74% (95 of 1,410), a moderate increase from 4.6% (60 of 1,304) in November;
• Positivity in the wean-to-market category in December was 10.45% (148 of 1,416), similar to 9.06% (124 of 1,369) in November;
• Overall PEDV-percentage of positive cases was within state-specific baselines in all 11 monitored states;
•Overall, 2.43% of 206 samples had mixed PEDV genotype detection in December, a moderate increase from 0% of 96 in November;
Overall, 13.34% of 712 cases tested M. hyopneumoniae-positive cases in December, a moderate decrease from 17.95% of 808 in November;
•Positivity in the adult/sow category in December was 6.32% (16 of 253), a moderate decrease from 10.7% (26 of 243) in November;
• Positivity in the wean-to-market category in December was 21.05% (68 of 323), a moderate decrease from 25% (105 of 420) in November;
• Overall MHP-percentage of positive cases was 3 standard deviations above state-specific baselines SD, IL, IN and OK